Welcome to our dedicated page for Pulse Biosciences news (Ticker: PLSE), a resource for investors and traders seeking the latest updates and insights on Pulse Biosciences stock.
Pulse Biosciences develops bioelectric medicine technology based on its proprietary nPulse platform, which uses nanosecond pulsed field ablation energy to deliver nanosecond electrical pulses for non-thermal cell clearing. Company news commonly centers on the nPulse Cardiac Catheter System for atrial fibrillation, clinical study disclosures, feasibility data, and presentations at electrophysiology and healthcare conferences.
Recurring updates also cover the company's work in selected applications such as surgical soft tissue ablation, investor presentations and analyst events, executive leadership changes, operating and financial results, governance matters, and capital-structure disclosures related to its common stock and financing programs.
Pulse Biosciences (Nasdaq: PLSE) announced first patient enrollments in a multi-center, first-in-human feasibility study of the nPulse Vybrance Percutaneous Electrode System to treat T1N0M0 papillary thyroid microcarcinoma (tumors <1.5 cm).
Initial procedures were completed at Sarasota Memorial and UT MD Anderson. The system has prior FDA 510(k) clearance for soft tissue ablation and is now being evaluated under an IDE for thyroid applications; a total of 30 patients are planned across two sites.
Pulse Biosciences (Nasdaq: PLSE) reported long-term clinical durability from a first-in-human study of the nPulse Vybrance system for benign thyroid nodule ablation using nsPFA energy. At 15–22 months post-treatment, treated nodules showed an average 74% volume reduction, with no regrowth and no serious adverse events.
Patient satisfaction was high: 100% Highly Satisfied for cosmetic outcome and 95% Highly Satisfied overall. The extension followed 21 patients and was presented March 6, 2026.
Pulse Biosciences (Nasdaq: PLSE) will present at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference on Wednesday, March 18, 2026 at 10:40 am ET. Management will participate in a virtual fireside chat about the company and its nPulseâ„¢ nanosecond PFAâ„¢ technology.
A live and recorded webcast will be available on the company's Events Calendar and Presentations page at investors.pulsebiosciences.com.
Pulse Biosciences (Nasdaq: PLSE) announced its nPulse Vybrance system will be featured in a podium presentation and a product theatre at the North American Society for Interventional Thyroidology meeting, March 6-7, 2026 in Portland.
Presentations include an interim feasibility report reviewing long-term follow-up up to 22 months for patients treated with nsPFA for benign, symptomatic thyroid nodules; a roundtable will discuss mechanism, results, and case studies.
Pulse Biosciences (Nasdaq: PLSE) announced inducement equity awards approved February 18, 2026 under its 2017 Inducement Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The Compensation Committee granted stock options to two new employees to purchase up to 19,000 shares at an exercise price of $25.46 per share, equal to the February 18, 2026 closing price, vesting time-based over four years with 1/4 vesting annually, subject to continued employment and plan terms.
Pulse Biosciences (Nasdaq: PLSE) will present at the 46th Annual TD Cowen Healthcare Conference in Boston on Wednesday, March 4, 2026 at 1:10 pm ET. Management will deliver a live presentation and a webcast will be available.
A recorded webcast will be posted on the company’s investor Events Calendar and Presentations page at http://investors.pulsebiosciences.com/.
Pulse Biosciences (Nasdaq: PLSE) reported Q4 and full-year 2025 results and business updates on Feb 19, 2026. Key clinical milestones include FDA IDE approvals to start pivotal studies for the nPulse Cardiac Catheter System and surgical nPulse Cardiac Surgery System, and 100% 6‑month procedural success in a feasibility AF study.
Financials: Q4 revenue $264k, FY2025 revenue $350k, GAAP net loss Q4 ($17.4M) and FY ($72.8M); cash $80.7M at year-end.
Pulse Biosciences (Nasdaq: PLSE) presented late-breaking first-in-human feasibility data for the nPulse Cardiac Catheter at the AF Symposium on February 6, 2026. Key findings: 100% procedural success at 6 months (75/75), 96% at 12 months (45/47), average 16.1 applications, procedure time 65 ± 28 minutes, fluoroscopy 9.8 ± 5.8 minutes, left atrial dwell 21.0 ± 13.3 minutes, and 1.3% SAE rate (2/150). The study has treated 165 patients to date across nine European investigators and continues into a pivotal IDE study.
Pulse Biosciences (Nasdaq: PLSE) will report fourth quarter and full year 2025 business updates and financial results after market close on February 19, 2026. Management will host a conference call at 1:30 PM PT / 4:30 PM ET.
Investors can join by phone (U.S. 1-800-715-9871; international 1-646-307-1963, Conference ID 7647402) or via a live and recorded webcast on the company investor website.
Pulse Biosciences (Nasdaq: PLSE) will feature its nPulse Cardiac Catheter at the 31st Annual AF Symposium (Feb 5-7, 2026) in Boston, including a late-breaking clinical science session, a live case transmission, and a poster showing preclinical lesion-depth data.
Presentations include 6‑ and 12‑month follow-up from a 150‑patient feasibility experience at three European centers and a live broadcast from Na Homolce Hospital demonstrating EnSiteX™ 3D mapping integration.